31 results

One-year results from the FUTURE-II trial

18 May 2021

A decade already passed from the first use of bioresorbable vascular scaffold in percutaneous coronary interventions. The first studies - by using surrogate endpoints - showed some superiority of BRS vs. metallic drug-eluting stent in terms of the so-called vascular restoration therapy with recovery of vasomotion...

PACMAN AMI: Effects of Alirocumab on Coronary Atherosclerosis Assessed by Serial Multimodality Intracoronary Imaging in Patients With Acute Myocardial Infarction

03 Apr 2022

Nicola Ryan provides a PICOT analysis of PACMAN AMI: a double-blind, placebo-controlled, randomized trial presented at ACC 2022 and simultaneously published in JAMA.

Author

Nicola Ryan

Comparison of noncompliant balloon with drug-coating balloon angioplasties for side branch after provisional stenting for patients with true coronary bifurcation lesions: The prospective, multicenter, randomized DCB-BIF Trial

03 Nov 2024

Aaysha Cader provides her take on the DCB-BIF Trial presented by Shao-Liang Chen at TCT 2024 in Washington.

Author

Aaysha Cader

Performing BASILICA: a step-by-step guide to prevent coronary obstruction during TAVI

12 Sep 2025

Author

Ahmed Abdelhafez

Author

Mohamed Abdel-Wahab

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

05 Sep 2023

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Author

Alessandro Sticchi

Post-TAVI cardiac arrest associated to acute coronary occlusion: facing the storm to gain calm

26 Jan 2024

Observe this TAVI case featuring pulseless electrical activity due to an unforeseen acute occlusion of the right coronary artery, and discover the strategies employed to address and resolve this critical complication.

Authors :

Juan Guzmán Olea, Gonzalo Tolosa Dzul, Beatriz Villegas González, Jonathan Uribe González,  Guillermo Arenas Fonseca, Tomás Herrera Arzola, Rosa Gutiérrez Castañeda, Víctor Sustaita Cerda, Raúl Cruz Palomera, Arely Méndez Mercado, Darío Valencia González, Carlos Javier González Álvarez, Héctor Hugo Escutia Cuevas, Daniel Iván Pérez Vásquez, Gabriel Guzmán Olea.Specialty Hospital, Puebla, IMSS, México

The PROTECTED TAVR study: Cerebral embolic protection during transcatheter aortic valve replacement

18 Sep 2022

Jonathan Curio provides his take on the PROTECTED TAVR study which was presented by Samir R. Kapadia at TCT 2022. The aim was to evaluate whether TAVR with cerebral embolic protection would reduce the rate of clinical stroke in transfemoral TAVR.

Author

Jonathan Curio

Frequency and safety of bioprosthetic valve fracture in patients undergoing valve in valve TAVR for failed surgical valves using the SAPIEN 3/Ultra Valves: Insights from real-world data

19 Sep 2022

Michele Pighi provides his take on this trial which aimed to compare the safety and efficacy of VIV-TAVI with or without bioprosthetic valve fracture. It was presented by Santiago Garcia during the TCT Congress 2022.

Author

Michele Pighi

ISAR REACT 5 - Ticagrelor versus prasugrel in patients with acute coronary syndrome

03 Sep 2019

At the ESC Congress 2019 in Paris, Stefanie Schuepke presented the results of the ISAR REACT 5 study. Read this analysis by Francesco Costa and view a short interview with Stefanie Schuepke.

Author

Francesco Costa

Cardiac biomarkers in patients with asymptomatic severe aortic stenosis: primary biomarker analysis from the EARLY TAVR Trial

01 Apr 2025

Elad Asher provides his take on the primary biomarker analysis from the EARLY TAVR Trial presented by Brian R. Lindman at ACC.25 in Chicago.

Author

Elad Asher

SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk

07 Nov 2021

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...

Author

Paola Redaelli

Author

Michele Pighi